A small Egyptian drugmaker has just delivered the kind of turn that makes investors sit up: from a loss to a solid profit in a single year, while sales jumped by nearly three-quarters. Full nameMacro Group Pharmaceuticals – Macro Capital S.A.E. Tickers / exchangeMCRO / Egyptian Exchange (EGX) HeadquartersCairo, Egypt SectorPharmaceuticals and consumer healthcare EmployeesNot published in available sources Market valueNot published in available sources Yearly salesEGP 894.54m (US$17.07m) — FY2025 Net profitEGP 115.73m (US$2.21m) — FY2025 Net margin12.9% (our calculation) Return on equityNot published in available sources Price-to-earningsNot published …
Company Intelligence — Institutional Access
This dossier is part of our Company Intelligence database.
Full profiles, exchange dossiers and the regional intelligence briefs are available to institutional subscribers. Professional from US$490/year, Corporate US$1,450, Institutional US$3,900.
See institutional access →Already a subscriber? Log in.
Part of LatAm Company Intelligence
This company profile belongs to The Rio Times' research on every listed company and exchange in Latin America and the Caribbean. Browse the full intelligence hub →
Latest coverage
Tinubu Macron Dinner: Nigeria’s President Meets France’s Leader in Paris
Peter Thiel Vista Energy: Thiel Macro Buys Vaca Muerta Stake
Macron Bets on Kenya in a €23 Billion Pivot to Anglophone Africa
Macron and Meloni Are Opposites. They Just Found Reasons to Agree.
Not ready to buy? Try Company Intelligence free for 14 days →
Editorial responsibility: Matthias Camenzind, Editor-in-Chief · Editorial standards · Report an error
Read More from The Rio Times
The Rio Times · Power Map
See who really holds power in Latin America
Click to open the Power Map →